Effects of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of mavoglurant, a drug, on alcohol craving and consumption among heavy drinkers diagnosed with Alcohol Use Disorder (AUD). Participants will undergo a double-blind, placebo-controlled design, where they will receive either mavoglurant or a placebo during two lab sessions separated by a washout period. The study includes Cue Exposure and Alcohol Drinking Paradigms to assess the drug's effects on craving and drinking behavior, with follow-up appointments scheduled one week and one month after the sessions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies).
2. Ability to read English at 6th grade level or higher.
3. Meet DSM-V criteria for moderate or severe Alcohol Use Disorder (AUD).
4. Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the Alcohol Drinking Paradigm (ADP).

Exclusion Criteria:

1. Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months.
2. Meet current Diagnostic and Statistical Manual v.5 (DSM-V) criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder.
3. Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines and barbiturates.
4. Psychotic or other severe psychiatric disorders as determined by clinical evaluation (Structured Clinical Interview for DSM-V; SCID). Note that if a subject endorses any harm/risk behaviors (e.g. suicidal/homicidal risk) a licensed clinician will be consulted immediately.
5. Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months.
6. Medical conditions that would contraindicate the consumption of alcohol or use of mavoglurant.
7. Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) \>3 times upper limit of normal (ULN); alanine aminotransferase (ALT) \> 3 times ULN; total bilirubin \>1.5 times ULN; serum creatinine \>2.0 times ULN.
8. Neurological trauma or disease, delirium or hallucinations, or clinically significant or unstable medical conditions, including uncontrolled hypertension or diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases, which in the opinion of the study physician and Principal Investigator, may put the patient at risk because of participation in the study.
9. Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores of 8 or greater or a history of significant repeated alcohol withdrawals to reduce the likelihood of withdrawal symptomatology if subjects reduce their drinking.
10. Women who are pregnant or nursing.
11. Participants who refuse to use a reliable method of birth control.
12. Subjects who report disliking spirits will be excluded because hard liquor will be provided during the ADP.
13. Subjects who have taken any investigational drug within 4 weeks of the anticipated date of the first study dose.
14. Individuals who report heavy drinking days in the 2 days prior to their intake appointment but have a negative ethyl glucuronide (EtG) test to rule out subjects who are misrepresenting their drinking history.
15. Subjects who have donated blood within the past 6 weeks.

Where it's running

• Connecticut Mental Health Center (SAC and SATU)
  New Haven, Connecticut, United States Recruiting
• Yale New Haven Hospital
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Suchitra Krishnan, PhD — Yale University
• Study coordinator: Suchitra Krishnan, PhD
• Email: suchitra.krishnan-sarin@yale.edu
• Phone: 203-974-7595

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Probenecid to reduce alcohol craving and consumption

  This trial will test whether taking daily probenecid (2 g/day) reduces craving and drinking in adults with moderate-to-severe alcohol use disorder.

  Recruiting Phase 2 Brown University · Providence, Rhode Island · NCT07118618

• Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder

  This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.

  Recruiting Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07825818

• Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD

  A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07824089

• Do beverage cues drive craving in adults with AUD

  In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.

  Recruiting University of Texas Southwestern Medical Center · Dallas, Texas · NCT07788716

• Semaglutide for Alcohol Use Disorder and Obesity: Testing 1.0 mg and 2.0 mg vs Placebo

  We’re testing two doses of semaglutide to see if they reduce alcohol craving and use in adults with alcohol use disorder and obesity compared with placebo.

  Recruiting at 2 sites Phase 1 Yale University · New Haven, Connecticut and 1 other locations · NCT07772960

• TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder

  A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07735585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.